Artículos del autor

solaci

Day 3

OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific...
solaci -
Day 3

DESTINY TRIAL: Stent de hastes finas com polímero eluidor de sirolimus

Pedro Lemos2014-09-16
solaci -
Day 4

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences...
solaci -
Day 4

SYMPLICITY FLEX: Renal sympathetic denervation in patients with resistant hypertension

Mild refractory hypertension patients were defined as those with daytime systolic BP 135-149 and diastolic BP 90-94...
solaci -
Day 4

PRIMA: Closure of patent foramen ovale in patients with migraine with aura refractory

It is hypothesized that the presence of a right-left shunt can trigger migraine attacks. The aim of...
solaci -
Day 3

BRIGHT: Bivalirudin versus heparin versus heparin plus tirofiban in primary angioplasty

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB...
solaci -
Day 3

ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination...
solaci -
Day 3

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus...
solaci -